Evidence map›Paper›PMID 22489605›Full record

ArticleJournal of the American Chemical Society2012

Site-selective glycosylation of hemoglobin with variable molecular weight oligosaccharides: potential alternative to PEGylation.

Thomas J Styslinger, Ning Zhang, Veer S Bhatt, Nicholas Pettit, Andre F Palmer, Peng G Wang

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Thomas J StyslingerDepartment of Chemistry, The Ohio State University, Columbus, Ohio 43210, USA.
Ning Zhang
Veer S Bhatt
Nicholas Pettit
Andre F Palmer
Peng G Wang
The Ohio State University · US

Funding

Training and Education CoreU54NS058183 · NINDS · U.S. ARMY MEDICAL RESEARCH INST CHEM DEF · PI CERASOLI, DOUGLAS MARK · 2006 to 2013
$20.6M
Biosynthesis of PolysaccharidesR01GM085267 · NIGMS · OHIO STATE UNIVERSITY · PI WANG, PENG GEORGE · 2009 to 2017
$2.4M
Mechanically Stable Blood SubstitutesR01HL078840 · NHLBI · UNIVERSITY OF NOTRE DAME · PI PALMER, ANDRE FRANCIS · 2006 to 2010
$2.1M
Investigation on Oligosaccharides as Antimicrobial and PrebioticsR01HD061935 · NICHD · OHIO STATE UNIVERSITY · PI WANG, PENG GEORGE · 2009 to 2013
$1.6M
Enhanced O2 Delivery to C3A HepatocytesR01DK070862 · NIDDK · UNIVERSITY OF NOTRE DAME · PI PALMER, ANDRE FRANCIS · 2006 to 2009
$585k
NHLBI NIH HHS R01 HL078840NHLBI NIH HHS R01HL078840NICHD NIH HHS R01 HD061935NIDDK NIH HHS R01 DK070862NIDDK NIH HHS R01DK070862NIGMS NIH HHS R01 GM085267
6 · The paper itself

Abstract

Poly(ethylene glycol) (PEG) conjugation (i.e., PEGylation) is a commonly used strategy to increase the circulatory half-life of therapeutic proteins and colloids; however, few viable alternatives exist to replicate its functions. Herein, we report a method for the rapid site-selective glycosylation of proteins with variously sized carbohydrates, up to a molecular weight (MW) of 10,000, thus serving as a potential alternative for PEGylation. More importantly, the method developed has two unique features. First, traditional protecting group strategies that typically accompany the modification of the carbohydrate fragments are circumvented, allowing for the facile site-selective glycosylation of a desired protein with variously sized glycans. Second, the methodology employed is not limited by oligosaccharide size; consequently, glycans of MW similar to that of PEG, used in the PEGylation of therapeutic proteins, can be employed. To demonstrate the usefulness of this technology, hemoglobin (Hb) was site-selectively glycosylated with a series of carbohydrates of increasing MW (from 504 to ∼10,000). Hb was selected on the basis of the vast wealth of biochemical and biophysical knowledge present in the literature and because of its use as a precursor in the synthesis/formulation of artificial red blood cell substitutes. Following the successful site-selective glycosylation of Hb, the impact of increasing the glycan MW on Hb's biophysical properties was investigated in vitro.

Indexed as

AnimalsCattleCircular DichroismCrystallography, X-RayGlycosylationHemoglobinsModels, MolecularOligosaccharidesOxygenPolyethylene GlycolsHemoglobinsOligosaccharidesOxygenPolyethylene Glycols

Identifiers

PMID22489605
PMCPMC3353419
OpenAlexW2088740181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.